Neuropathix

From Wikipedia, the free encyclopedia
Neuropathix Inc.
TypePublic
OTCQB: NPTX
IndustryPharmaceutical Biotechnology
FoundersDean Petkanas, Thoma Kikis
HeadquartersDoylestown, Pennsylvania
Total assetsPatents US 9611213 , US 10004722 
Websiteneuropathix.com


Neuropathix, Inc. is a biopharmaceutical company based in Doylestown, Pennsylvania focused on the research and development of pain management and neuroprotective therapeutics.[1]

In 2016, through the company's subsidiary Kannalife, Neuropathix discovered KLS-13019[2][3][4][5] along with other therapeutic agents that prevent neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Neuropathix family of monotherapeutic small molecules are focused on treating oxidative stress-related diseases, chronic pain management and neurodegenerative disorders.

Neuropathix is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County to treat Chemotherapy-induced peripheral neuropathy, Hepatic encephalopathy, Mild Traumatic Brain Injury and CTE.[6]

References[]

  1. ^ Rees, Victoria (November 26, 2020). "Cannabinoid series: a CBD-inspired molecule to increase bioavailability". European Pharmaceutical Review. Retrieved 2020-11-26.
  2. ^ Kinney WA, McDonnell ME, Zhong HM, Liu C, Yang L, Ling W, Qian T, Chen Y, Cai Z, Petkanas D, et al. (April 2016). "Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability". ACS Medicinal Chemistry Letters. 7 (4): 424–8. doi:10.1021/acsmedchemlett.6b00009. PMC 4834656. PMID 27096053.
  3. ^ Brenneman DE, Petkanas D, Kinney WA (September 2018). "Pharmacological Comparisons Between Cannabidiol and KLS-13019". Journal of Molecular Neuroscience. 66 (1): 121–134. doi:10.1007/s12031-018-1154-7. PMC 6150782. PMID 30109468.
  4. ^ Brenneman DE, Kinney WA, Ward SJ (August 2019). "Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity". Journal of Molecular Neuroscience. 68 (4): 603–619. doi:10.1007/s12031-019-01321-z. PMC 6615992. PMID 31077084.
  5. ^ Foss JD, Farkas DJ, Huynh LM, Kinney WA, Brenneman DE, Ward SJ (April 2021). "Behavioral and pharmacological effects of cannabidiol (CBD) and the CBD analogue KLS‐13019 in mouse models of pain and reinforcement". British Journal of Pharmacology. doi:10.1111/bph.15486. PMID 33822373.
  6. ^ Baskin, Ben (July 12, 2016). "How cannabis is helping one company research treatment of CTE". Sports Illustrated. Retrieved 2016-07-12.

External links[]

Retrieved from ""